• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    8/1/24 4:17:22 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    SC 13G 1 tm2420635d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Artiva Biotherapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    04317A107

    (CUSIP Number)

     

    July 22, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

    ¨

    Rule 13d-1(b)

    Rule 13d-1(c)

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   04317A107
    1.

    Names of Reporting Persons

    5AM Ventures VI, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,171,250 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,171,250 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,171,250 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.0% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)This Schedule 13G is filed by 5AM Ventures VI, L.P. (“Ventures VI”), 5AM Partners VI, LLC (“Partners VI”), 5AM Opportunities II, L.P. (“Opps II”), 5AM Opportunities II (GP), LLC (“Opps II GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Parmar” and, with Ventures VI, Partners VI, Opps II, Opps II GP and Schwab collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    2 

     

     

    CUSIP No.   04317A107
    1.

    Names of Reporting Persons

    5AM Partners VI, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,171,250 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,171,250 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,171,250 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.0% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO       

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    3 

     

     

    CUSIP No.   04317A107
    1.

    Names of Reporting Persons

    5AM Opportunities II, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,182,054 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,182,054 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,182,054 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are directly held by Opps II. Opps II GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opps II GP. Each of Opps II GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opps II.

     

    (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    4 

     

     

    CUSIP No.   04317A107
    1.

    Names of Reporting Persons

    5AM Opportunities II (GP), LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,182,054 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,182,054 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,182,054(2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The shares are directly held by Opps II. Opps II GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opps II GP. Each of Opps II GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opps II.

     

    (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    5 

     

     

    CUSIP No.   04317A107
    1.

    Names of Reporting Persons

    Andrew J. Schwab

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    2,353,304 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    2,353,304 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,353,304 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    10.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Consists of (i) 1,171,250 shares of Common Stock held by Ventures VI and (ii) 1,182,054 shares of Common Stock held by Opps II. Partners VI is the sole general partner of Ventures VI and Opps II GP is the sole general partner of Opps II. Schwab and Parmar are the managing members of each of Partners VI and Opps II GP. Each of Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI and Opps II.

     

    (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    6 

     

     

    CUSIP No.   04317A107
    1.

    Names of Reporting Persons

    Kush Parmar

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    2,353,304 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    2,353,304 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,353,304 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    10.1 % (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Consists of (i) 1,171,250 shares of Common Stock held by Ventures VI and (ii) 1,182,054 shares of Common Stock held by Opps II. Partners VI is the sole general partner of Ventures VI and Opps II GP is the sole general partner of Opps II. Schwab and Parmar are the managing members of each of Partners VI and Opps II GP. Each of Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI and Opps II.

     

    (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    7 

     

     

    Item 1.
      (a)

    Name of Issuer

    Artiva Biotherapeutics, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

    5505 Morehouse Drive, Suite 100

    San Diego, CA 92121

     

    Item 2.
      (a)

    Name of Person Filing

    5AM Ventures VI, L.P. (“Ventures VI”)

    5AM Partners VI, LLC (“Partners VI”)

    5AM Opportunities II, L.P. (“Opps II”)

    5AM Opportunities II (GP), LLC (“Opps II GP”)

    Andrew J. Schwab (“Schwab”)

    Dr. Kush Parmar (“Parmar”)

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o 5AM Ventures

    4 Embarcadero Center, Suite 3110

    San Francisco, CA 94111

      (c) Citizenship  
        Entities: Ventures VI - Delaware
          Partners VI - Delaware
          Opps II - Delaware
          Opps II GP - Delaware
               
        Individuals: Schwab - United States
          Parmar - United States

      (d)

    Title of Class of Securities

    Common Stock, $0.0001 par value (“Common Stock”)

      (e)

    CUSIP Number

    04317A107

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable

     

    8 

     

     

    Item 4. Ownership
       
    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of August 1, 2024:

     

    Reporting
    Persons
     

    Shares Held
    Directly

      

    Sole
    Voting
    Power

      

    Shared

    Voting

    Power

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power

      

    Beneficial

    Ownership

      

    Percentage

    of Class (3)

     
    Ventures VI (1)   1,171,250    0    1,171,250            0    1,171,250    1,171,250    5.0%
    Partners VI (1)   0    0    1,171,250    0    1,171,250    1,171,250    5.0%
    Opps II (2)   1,182,054    0    1,182,054    0    1,182,054    1,182,054    5.1%
    Opps II GP (2)   0    0    1,182,054    0    1,182,054    1,182,054    5.1%
    Schwab (1)(2)   0    0    2,353,304    0    2,353,304    2,353,304    10.1%
    Parmar (1)(2)   0    0    2,353,304    0    2,353,304    2,353,304    10.1%

     

    (1)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (2)The shares are directly held by Opps II. Opps II GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opps II GP. Each of Opps II GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opps II.
       
     (3)This percentage is calculated based on 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission on July 22, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable

     

    9 

     

     

    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    10 

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 1, 2024

     

    5AM Ventures VI, L.P.   5AM Partners VI, LLC
         
    By: 5AM Partners VI, LLC   By: /s/ Andrew J. Schwab
    its General Partner     Name: Andrew J. Schwab
          Title: Managing Member
    By: /s/ Andrew J. Schwab      
      Name: Andrew J. Schwab      
      Title: Managing Member      

     

    5AM Opportunities II, L.P.   5AM Opportunities II (GP), LLC
         
    By: 5AM Opportunities II (GP), LLC   By: /s/ Andrew J. Schwab
    its General Partner     Name: Andrew J. Schwab
          Title: Managing Member
    By: /s/ Andrew J. Schwab    
      Name: Andrew J. Schwab    
      Title: Managing Member    
         
    /s/ Andrew J. Schwab    
    Andrew J. Schwab    
         
    /s/ Dr. Kush Parmar    
    Dr. Kush Parmar    

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    11 

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    12 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Artiva Biotherapeutics, Inc. is filed on behalf of each of us.

     

    Dated: August 1, 2024

     

    5AM Ventures VI, L.P.   5AM Partners VI, LLC
         
    By: 5AM Partners VI, LLC   By: /s/ Andrew J. Schwab
    its General Partner     Name: Andrew J. Schwab
          Title: Managing Member
    By: /s/ Andrew J. Schwab      
      Name: Andrew J. Schwab      
      Title: Managing Member      

     

    5AM Opportunities II, L.P.   5AM Opportunities II (GP), LLC
         
    By: 5AM Opportunities II (GP), LLC   By: /s/ Andrew J. Schwab
    its General Partner     Name: Andrew J. Schwab
          Title: Managing Member
    By: /s/ Andrew J. Schwab    
      Name: Andrew J. Schwab    
      Title: Managing Member    
         
         
    /s/ Andrew J. Schwab    
    Andrew J. Schwab    
         
    /s/ Dr. Kush Parmar    
    Dr. Kush Parmar    

     

     

    Get the next $ARTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

      SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

      1/29/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chief Medical Officer Banerjee Subhashis was granted 50,000 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:07:02 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Banerjee Subhashis

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:03:53 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Aslan Fred was granted 200,000 shares, increasing direct ownership by 92% to 416,665 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      3/7/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

      12/30/24 7:13:58 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

      Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

      8/13/24 7:24:03 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

      Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known

      4/28/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:27:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:15:09 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:26:49 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    SEC Filings

    See more

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

      10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:06:33 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:03:54 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Artiva Biotherapeutics Inc.

      DEFA14A - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      4/28/25 9:36:26 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

      SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      11/14/24 4:56:18 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

      SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      9/3/24 4:18:05 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

      SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      8/1/24 7:00:07 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care